Prepare for your Eli Lilly role

Master manufacturing optimization, drug economics, and diabetes/oncology expertise at a leading innovator.

Socratify AI

The Interview

What Eli Lilly is looking for

Operations Interview

Manufacturing & Drug Economics

01Cost of Goods Sold

02Supply Chain Optimization

03Pricing Strategy

04Manufacturing Scale-up

Therapy Interview

Therapeutic Area Strategy

01Disease Epidemiology

02Competitive Landscape

03Clinical Efficacy

04Market Dynamics

Leadership in diabetes and endocrinology innovation//Strong manufacturing efficiency and cost control//Growing oncology and immunology presence

Practice Library

Eli Lilly exercises

Ready to ace your Eli Lilly interview?

Prepare for your Eli Lilly role

Master manufacturing optimization, drug economics, and diabetes/oncology expertise at a leading innovator.

Socratify AI

The Interview

What Eli Lilly is looking for

Operations Interview

Manufacturing & Drug Economics

01Cost of Goods Sold

02Supply Chain Optimization

03Pricing Strategy

04Manufacturing Scale-up

Therapy Interview

Therapeutic Area Strategy

01Disease Epidemiology

02Competitive Landscape

03Clinical Efficacy

04Market Dynamics

Leadership in diabetes and endocrinology innovation//Strong manufacturing efficiency and cost control//Growing oncology and immunology presence

How It Works

Master Eli Lilly Manufacturing & Strategy

Practice drug economics and manufacturing strategy evaluated at Eli Lilly. · Click to expand

R&D Portfolio Strategy

Practitioner

Clinical Development

Practitioner

1Your Pharma Goals

2Pharma Case Prep

Your new diabetes drug has strong efficacy but manufacturing costs are 40% above target....

CASE INTERVIEWHard

Pharmaceuticals · Cost OptimizationEli Lilly

3Frameworks

Framework

Is our pipeline sufficiently diverse and mature across therapeutic areas?

What is the distribution of candidates across development stages?

Phase 3 success rate: 58% (industry avg 50-60%, indicating solid execution)

Average time to Phase 2: 4.2 years (target: <4 years, slightly behind)

How concentrated is our portfolio in any single therapeutic area or mechanism?

Top 3 programs represent 38% of pipeline potential (target: <40%, well-diversified)

Orphan drug allocation: 22% of programs (regulatory incentives: 7-yr exclusivity)

Are we executing clinical development efficiently and advancing candidates effectively?

What is our development timeline relative to competitors and patent life?

Average development cost: $2.6B from discovery to market (current: $2.1B, 19% below)

Median time to FDA approval: 7.8 years (industry avg 10-12 years, 25% faster)

Are our Phase 3 results competitive relative to existing standards of care?

Efficacy delta vs standard of care: 28% improvement (competitive threshold: >20%)

Safety profile: Adverse event rate 12% (standard of care: 18%, statistically superior)

Can we commercialize successfully and capture market share profitably?

What is the addressable market and realistic peak sales potential?

Addressable market for primary indication: $18.4B globally (3.2% CAGR category)

Peak sales forecast: $2.1B at 12% market share (10-year ramp, product reaches market 2027)

What are the manufacturing, pricing, and reimbursement dynamics?

Cost of goods sold: 18% of gross revenue (target: <20%, acceptable but room for optimization)

Expected net price after rebates: $4,200 per patient annually (vs competitor $5,100, 18% lower)

Portfolio Analysis

Distinctive

Clinical Strategy

Strong

Commercial Viability

Meeting Bar

Risk Assessment

Strong

4Feedback

How It Works

Master Eli Lilly Manufacturing & Strategy

Practice drug economics and manufacturing strategy evaluated at Eli Lilly. · Click to expand

1Your Pharma Goals

R&D Portfolio Strategy

Practitioner

Clinical Development

Practitioner

2Pharma Case Prep

Your new diabetes drug has strong efficacy but manufacturing costs are 40% above target....

CASE INTERVIEWHard

Eli Lilly